Full Press Release Details
Jasper Therapeutics Announces Closing of Public
Common Stock and Full Exercise of Underwriters' Option to Purchase
REDWOOD CITY, Calif., January 27, 2023 (GLOBE
NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a biotechnology company focused on developing novel
antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic
syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the closing of its previously announced underwritten
public offering of 69,000,000 shares of its common stock, at a public offering price of $1.50 per share, which includes the exercise in
full by the underwriters of their option to purchase up to 9,000,000 additional shares of common stock. The gross proceeds from this offering
are approximately $103.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Jasper.
Credit Suisse Securities (USA) LLC and William
Blair & Company, L.L.C. acted as the active book-running managers for the offering. Oppenheimer & Co. Inc. acted as a passive
book-running manager for the offering.
The securities described above were offered by
Jasper pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-267777) previously filed with the
Securities and Exchange Commission (the "SEC") on October 7, 2022 and declared effective by the SEC on October 18, 2022. A
final prospectus supplement and the accompanying prospectus relating to and describing the offering has been filed with the SEC. Electronic
copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by visiting the SEC's
website at www.sec.gov or by contacting Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New
York, NY 10010, by calling toll-free (800) 221-1037 or by emailing newyork.prospectus@credit-suisse.com, William Blair & Company,
L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by calling toll-free (800) 621-0687, or by emailing
prospectus@williamblair.com or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New
York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such state or jurisdiction.
Jasper is a clinical-stage biotechnology company
developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as
chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants
for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab
has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning
agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic
conditioning agent for gene therapy.
Forward-Looking Statements
Certain statements included in this press release
that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe,"
"may," "will," "estimate," "continue," "anticipate," "intend,"
"expect," "should," "would," "plan," "predict," "potential," "seem,"
"seek," "future," "outlook" and similar expressions that predict or indicate future events or trends
or that are not statements of historical matters. These statements are based on our current expectations and beliefs and are subject to
a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. The risks and uncertainties involved include those associated with general economic and market conditions and our ability
to satisfy closing conditions applicable to the offering, as well as other risk factors and matters set forth in our periodic filings
with the SEC, including our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and the final prospectus
supplement and the accompanying prospectus related to the public offering filed with the SEC. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available
by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether
as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
John Mullaly (investors)
Jeet Mahal (investors)
Lauren Barbiero (media)